Can-Fite BioPharma (NYSE:CANF) Now Covered by StockNews.com

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report issued on Saturday morning. The firm issued a sell rating on the stock.

Separately, D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Can-Fite BioPharma in a research note on Monday, March 3rd.

Can-Fite BioPharma Stock Up 4.3 %

Shares of NYSE:CANF opened at $1.63 on Friday. The company’s 50-day moving average price is $1.58 and its 200 day moving average price is $1.89. The company has a market cap of $5.77 million, a PE ratio of -0.91 and a beta of 1.12. Can-Fite BioPharma has a fifty-two week low of $1.29 and a fifty-two week high of $4.69.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers lifted its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 26,880 shares of the company’s stock after acquiring an additional 9,935 shares during the quarter. Rhumbline Advisers owned approximately 0.76% of Can-Fite BioPharma worth $44,000 as of its most recent filing with the SEC. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.